Issue link: https://uberflip.scri.com/i/1521062
0529/24SCR019-14/R3 Abstract Presentation Calendar ASCO® 2024 14 Saturday Friday Sunday Monday Tuesday Publication Only MONDAY, JUNE 3 RD 8:00am - 12:00pm Central Time (continued) Time Presentation Time Session Location Presentation Type Abstract Number Presentation Title 1st Author *SCRI First Author in Bold SCRI-Affiliated Coauthors Session Name 9:00am - 12:00pm Hall A Poster TPS6590 A first-in-human, phase 1, dose escalation study of SGR-2921 as monotherapy in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome. Weiss D Strickland S Hematologic Malignancies— Leukemia, Myelodysplastic Syndromes, and Allotransplant 9:00am - 12:00pm Hall A Poster TPS5637 Efficacy and safety of luveltamab tazevibulin vs investigator's choice of chemotherapy in patients with recurrent platinum-resistant ovarian cancer (PROC) expressing folate receptor alpha (FRα): The REFRaME-01 (GOG-3086, ENGOT- 79ov, and APGOT-OV9) phase 2/3 study. Oaknin A Monk B Gynecologic Cancer 9:00am - 12:00pm Hall A Poster TPS7091 A first-in-human study of the potent and highly selective BTK degrader ABBV-101 in patients with relapsed/ refractory B-cell malignancies. Chong E Fletcher L, Burke J Hematologic Malignancies— Lymphoma and Chronic Lymphocytic Leukemia 9:45 - 11:15am 10:15 - 10:21am S406 Oral LBA9512 Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial Weber JS McKean M Melanoma/Skin Cancers MONDAY, JUNE 3 RD 11:30am - 2:45pm Central Time Time Presentation Time Session Location Presentation Type Abstract Number Presentation Title 1st Author *SCRI First Author in Bold SCRI-Affiliated Coauthors Session Name 11:30am - 1:00pm 11:36 - 11:42am Hall D1 Oral 1015 H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (–) breast cancer (BC). Hamilton E Hamilton E, Wang J, Wright G, Kayali F Breast Cancer— Metastatic 11:30am - 2:30pm Hall D2 Oral Chair Naqash A Developmental Therapeutics— Immunotherapy 11:30am - 2:30pm 12:30 - 12:42pm Hall D2 Oral 2503 A phase 1/2 study of REGN7075 in combination with cemiplimab (cemi) in patients (pts) with advanced solid tumors: Efficacy and safety results. Segal N Johnson M Developmental Therapeutics— Immunotherapy 11:30am - 2:30pm 1:42 - 1:54pm Hall D2 Oral 2507 Phase 1 study (DRAGON) of SRK-181 (linavonkibart), a latent TGFβ1 inhibitor, combined with pembrolizumab in patients with anti- PD1 resistant advanced solid tumors: Updated results of expansion part. Vaishampayan U McKean M Developmental Therapeutics— Immunotherapy